Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

Organogenesis publishes positive 12-week clinical trial results for PuraPly AM in diabetic foot ulcers.

What the company is saying

Organogenesis Holdings Inc. is emphasizing the publication of results from the PREPARE 1 randomized controlled trial, which evaluated PuraPly AM plus standard of care versus standard of care alone for hard-to-heal diabetic foot ulcers. The company highlights that the trial achieved its primary endpoint and that statistically significant improvements in wound closure at 12 weeks were observed with PuraPly AM. Patrick Bilbo, Chief Operating Officer, frames these results as adding to a growing body of evidence for PuraPly AM, including real-world and health economics data. The announcement positions this evidence as a potential basis for future payer coverage decisions, suggesting a strategic focus on reimbursement and market access. Organogenesis claims peer-reviewed data is helping it gain market share while competitors without similar evidence are leaving the wound care market. The tone is confident and seeks to differentiate the company based on clinical validation and market positioning.

What the data suggests

The only quantitative data disclosed is that the PREPARE 1 trial showed statistically significant improvements in wound closure at 12 weeks for patients treated with PuraPly AM plus standard of care. The trial achieved its primary endpoint, and results are published in the Journal of Wound Care, lending credibility to the clinical outcome. No specific figures are provided regarding the magnitude of improvement, patient counts, or comparative statistics. There is no disclosure of financial metrics, revenue impact, or payer adoption rates. Claims about market share gains and competitor exits are not substantiated with data. The evidence supports clinical efficacy for PuraPly AM in diabetic foot ulcers, but the commercial and financial implications remain unquantified.

Analysis

The announcement highlights the publication of positive clinical trial results for PuraPly AM, specifically noting statistically significant improvements in wound closure at 12 weeks. These are realised, measurable outcomes and support a positive tone. However, the company extends these results with forward-looking claims about future coverage decisions and market share gains, neither of which are substantiated with data or timelines. There are no financial, operational, or profitability metrics disclosed, and no evidence of immediate commercial impact or payer adoption. The language around market differentiation and competitor exits is promotional and unsupported by numbers. The gap between narrative and evidence is moderate: while the clinical trial result is real, the broader commercial and financial implications remain speculative.

Risk flags

• ●The absence of detailed numerical results from the PREPARE 1 trial limits the ability to assess the true magnitude of clinical benefit, which could affect payer and clinician adoption.
• ●Forward-looking claims about future coverage decisions and market share gains are not supported by concrete data or timelines, introducing uncertainty about commercial impact.
• ●Competitive positioning is asserted without disclosure of actual market share data or specifics on competitor actions, making it difficult to evaluate the sustainability of any claimed advantage.

Bottom line

Organogenesis has published peer-reviewed clinical trial results showing that PuraPly AM improves wound closure in diabetic foot ulcers at 12 weeks, supporting its use in a challenging patient population. While this clinical milestone is credible and strengthens the product's evidence base, the announcement does not quantify the benefit or provide financial or adoption metrics. The company's narrative about future payer coverage and market share gains is forward-looking and not yet substantiated by operational or commercial data. Investors should recognize that while clinical validation is a necessary step for reimbursement and broader adoption, the timing and scale of financial impact remain uncertain. The most important takeaway is that Organogenesis has achieved a clinical milestone, but the path to material revenue growth from PuraPly AM is still dependent on future payer and market actions.

Announcement summary

(NASDAQ:ORGO) Organogenesis Holdings Inc. announced the publication of previously released results from the PREPARE 1 trial, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly® AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The PREPARE 1 trial achieved its primary endpoint. Results published in the Journal of Wound Care demonstrate statistically significant improvements in wound closure at 12 weeks among patients treated with PuraPly® AM plus SoC. The company states that this provides clinical evidence supporting the use of PuraPly® AM in one of the most costly and difficult-to-treat chronic wound populations. Patrick Bilbo, Chief Operating Officer of Organogenesis, commented that the PREPARE study adds to the company's growing body of data for PuraPly AM, including real-world evidence from registry and comparative effectiveness studies, as well as health economics and outcomes research. Bilbo stated that the company expects this evidence to form the basis for future coverage decisions for PuraPly AM. He also noted that peer-reviewed data continues to differentiate Organogenesis in a recalibrated market where the company is gaining share while competitors without comparable evidence are pivoting away from wound care or exiting the market. PuraPly® AM is described as a patent-protected native, cross-linked extracellular matrix scaffold with sustained antimicrobial effectiveness within the product to support wound healing as a protective barrier. PuraPly® AM is indicated for the management of partial- and full-thickness wounds, including diabetic foot ulcers, pressure injuries, venous leg ulcers, surgical wounds, and traumatic wounds. The company highlights its focus on the development, manufacture, and commercialization of solutions for the Advanced Wound Care and Surgical and Sports Medicine markets. Organogenesis offers a comprehensive portfolio of regenerative and tissue products to address patient needs across the continuum of care.

Disagree with this article?